Reuters logo
BRIEF-Cytrx reports Q1 loss per share $0.10
May 10, 2017 / 1:34 PM / 4 months ago

BRIEF-Cytrx reports Q1 loss per share $0.10

May 10 (Reuters) - Cytrx Corp

* Cytrx reports first quarter 2017 financial results

* Q1 loss per share $0.10

* Cytrx corp - goal is to submit a rolling nda under section 505(b)(2) to FDA in Q4 of 2017 for aldoxorubicin

* Cytrx Corp- commercial launch of aldoxorubicin is projected for 2018 in U.S

* Cytrx Corp - Cytrx also plans to discuss with European Medicines Agency a path to filing a marketing authorization application. For aldoxorubicin Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below